

295334US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE MAIL STOP PCT

IN RE APPLICATION OF:

Haruyasu YAMAGUCHI, et al.

GAU:

SERIAL NO: 10/589,969

FILED:

August 18, 2006

EXAMINER:

FOR:

MONOCLONAL ANTIBODY AND USE THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Surinder Sachar

Registration No. 34,423

Customer Number

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

		015 = 40								
•	湿	NOV 2 0 2006				SHE	EΤ	1	OF	1
Form PTO 1449 (Modified)	-/9	PADESTENT AND TRAD	OF COMMERCE DEMARK OFFICE	ATTY DOCKET NO. 295334US0PCT	SERIAL NO. 10/589,969					
				APPLICANT						
LIST OF	REFE	RENCES CITED BY APP	PLICANT	Haruyasu YAMAGUCHI, et al.						
				FILING DATE	GROUP					
				August 18, 2006						
				U.S. PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS			IG DATE ROPRIA	
	AA	!								
	AB	ļ			 					
	AC		ļ		\vdash					
	AD		l	<u> </u>			<u> </u>			
FOREIGN PATENT DOCUMENTS										
		DOCUMENT NUMBER	DATE	COUNTRY		TRAN: YES		SLAT'	SLATION NO	
	AE	94 17197	08-04-94	WO (with English abstract)					NO	
	AF	0 125 023	11-14-84	EP					NO	
	AG	0 239 400	09-30-87	EP					NO	
	AH	90 07861	07-26-90	wo					NO	
	Al	94 20632	09-15-94	WO (with English abstract)					NO	
	AJ									
	AK									
	AL									
	AM									
	AN									
		OTHER RE	FERENCES (Including Author, Title, Date, Pertinent	Pages, et	.c.)				
	AO MATHEWS, Paul M. et al.," Calpain Activity Regulates the Cell Surface Distribution of Amyloid Precursor Protein", The Journal of Biological Chemistry, Vol. 277, No. 39, pgs. 36415-36424, 2002.									
	AP	VANDERMEEREN, Marc et al.," The Functional y-Secretase Inhibitor Prevents Production of Amyloid β 1-34 in Human and Murine Cell Lines", Neuroscience Letters, Vol. 315, No. 3, pgs. 145-148, 2001.								
	AQ	MATHEWS, Paul M. et al.," Alzheimer's Disease-Related Overexpression of the Cation-Dependent Mannose 6-Phosphate Receptor Increases AB Secretion", The Journal of Biological Chemistry, Vol. 277, No. 7, pgs, 5299-5307, 2002.								
	AR	JANUS, Christopher et al." Aß Peptide Immunization Reduces Behavioural Impairment and Plaques in a Model of Alzheimer's Disease", Letters to Nature, Vol. 408, No. 6815, pgs. 978-983, 2000.								
	AS~	TAMAOKA, Akira," Alzhemer-Byo no Kotai Ryoho", Gendai Iryo, Vol. 34, No.1, pgs. 237-244, 2002.								
	AT	KINEBUCHI, Miyuki et al.," A Novel Cell Surface Antigen Involved in Thymocyte and Thymic Epithelial Cell Adhesion ¹ ", The Journal of Immunology, Vol. 146, NO. 11, pgs. 3721-3728, 1991.								
	AU	MORISHIMA-KAWASHIMA, Maho et al.," Effect of Apolipoprotein E Allele ε4 on the Initial Phase of Amyloid β-Protein Accumulation in the Human Brain", American Journal of Pathology, Vol. 157, No. 6, pgs. 2093-2099, 2000.								
	AV	ERLANGER, Bernard F. et al.," Steroid-Protein Conjugates", Departments of Microbiology, Biochemistry, and Obstetrics, and Gynecology, Collage of Physicians, Columbia University, Vol.234, No. 5, pgs. 1090-1094, 1958.								
	AW	KARU, Alexander E. et al.," Synthesis of Haptens and Derivation of Monoclonal Antibodies for Immunoassay of the Phenylurea Herbicide Diuron", J. Agric. Food Chem., Vol. 42, NO. 2, pgs. 301-309, 1994.								
	AX	YAZAKI, Paul J. et al.," Humanization of the Anti-CEA T84.66 Antibody Based on Crystal Structure Data", Protein Engineering, Design & Selection, Vol.17, No. 5, pgs. 481-489, 2004.								
	AY	CARTER, Paul et al.," Humanization of an Anti-p 185 ^{HER2} Antibody for Human Cancer Therapy", Proc. Natl. Acad. Sci., Vol. 89, pgs. 4285-4289, 1992.								
	AZ	KOBAYASHI, Tobinai K. et al.," Feasibility and Pharmacokinetic Study of a Chimeric Anti-CD-20 Monoclonal Antibody (IDEC-C2B8, Rituximab) in Relapsed B-Cell Lymphoma. The IDEC-C2B8 Study Group.", Ann. Oncol., Vol. 9, No. 5, pgs. 1-2, 1998.						ched		
Examiner	ı				Date Cons	sidered				

U.S. PCT Application Serial No: 10/589,969

Filed: August 18, 2006

Haruyasu YAMAGUCHI, et al. Docket No. 295334US 0PCT

STATEMENT OF RELEVANCY

- 1) References AO AS have been cited in the International Search Report. A copy of these references is being submitted herewith.
- 2) References have been cited in the corresponding Search Report. A copy of these references is being submitted herewith.
- 3) References AT AZ and AE AI are discussed in the specification. A copy of these references is being submitted herewith.
- 4) References are additional prior art known to Applicant. A copy of these references is being submitted herewith.